Bruker Daltonics Introduces Powerful PTMscan(TM) on its High-Capacity Ion Trap PTM Discovery System(TM)Bruker Daltonics Introdu

At Pittcon 2006, Bruker Daltonics today announces the
release of a powerful, novel PTMscan(TM) on its PTM Discovery
System(TM). The PTM Discovery System incorporates electron transfer
dissociation (ETD) in Bruker Daltonics' highly successful HCTultra(TM)
high-capacity ion trap mass spectrometer, the world's first and only
commercial system with fully integrated ETD capability. ETD
fragmentation breaks the peptide backbone non-ergodically and
preserves functionally important post-translational modifications
(PTMs), such as phosphorylation and glycosylation.
   The newly introduced PTMscan can now detect PTMs by first
screening for specific neutral losses during collision-induced
dissociation (CID), and then triggering automatic, data-dependent ETD
experiments on the fly. A particularly important PTMscan, called
Phospho-PTMscan(TM) enables the automated detection and localization
of phosphorylations of peptides and small proteins. Similar
Glyco-PTMscan(TM) methods are supported as well.
   Dr. Michael Schubert, Executive Vice President of Bruker
Daltonics, commented: "Last year, we introduced the world's first
high-capacity ion trap with ETD capability. This year, the PTMscan
methods further extend our customers' ability for automated,
intelligent phosphorylation and glycosylation characterization. While
similar PTM-analysis capabilities have been available on our
apex(R)-Qe FTMS systems, PTMscan now also enables this important
branch of proteomics on our robust, ultra-high sensitivity ion traps.
This further establishes Bruker Daltonics as the leader in PTM and
proteomics research by mass spectrometry."
   Pittcon 2006, the 57th Pittsburgh Conference and Exposition on
Analytical Chemistry and Applied Spectroscopy, is being held from
March 13-16 in Orlando, Florida in the Orange County Convention
Center. Bruker Daltonics will exhibit at booth #3155.

   ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker
Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer
and provider of life science, materials research, and industrial X-ray
analysis tools. Bruker Daltonics is a leading developer and provider
of innovative life science tools based on mass spectrometry. Bruker
Daltonics also offers a broad line of nuclear, biological and chemical
(NBC) detection products for defense and homeland security. For more
information, please visit www.bruker-biosciences.com

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.
These and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-K, our most recent quarterly
reports on Form 10-Q, and our current reports on Form 8-K. We disclaim
any intent or obligation to update these forward-looking statements.